5MY4

Structure of Pyroglutamate-Abeta-specific Fab c#17 in complex with human Abeta-pE3-12PEGb

Summary for 5MY4

• Entry DOI: 10.2210/pdb5my4/pdb
• Descriptor: Fab c#17 light chain, Fab c#17 heavy chain, Pyroglutamate-Abeta pE3-12-PEGb, ... (4 entities in total)
• Functional Keywords: alzheimer's disease, pyroglutamate abeta, monoclonal antibody, fibrillation, immune system
• Biological source: Mus musculus; More
• Total number of polymer chains: 3
• Total formula weight: 49951.45

Authors

Parthier, C.,Piechotta, A.,Stubbs, M.T. (deposition date: 2017-01-25, release date: 2017-06-28, Last modification date: 2024-11-20)

Primary citation

Piechotta, A.,Parthier, C.,Kleinschmidt, M.,Gnoth, K.,Pillot, T.,Lues, I.,Demuth, H.U.,Schilling, S.,Rahfeld, J.U.,Stubbs, M.T.
Structural and functional analyses of pyroglutamate-amyloid-beta-specific antibodies as a basis for Alzheimer immunotherapy.
J. Biol. Chem., 292:12713-12724, 2017

PubMed Abstract: Alzheimer disease is associated with deposition of the amyloidogenic peptide Aβ in the brain. Passive immunization using Aβ-specific antibodies has been demonstrated to reduce amyloid deposition both and Because N-terminally truncated pyroglutamate (pE)-modified Aβ species (Aβ) exhibit enhanced aggregation potential and propensity to form toxic oligomers, they represent particularly attractive targets for antibody therapy. Here we present three separate monoclonal antibodies that specifically recognize Aβ with affinities of 1-10 nm and inhibit Aβ fibril formation application of one of these resulted in improved memory in Aβ oligomer-treated mice. Crystal structures of F-Aβ complexes revealed two distinct binding modes for the peptide. Juxtaposition of pyroglutamate pE3 and the F4 side chain (the "pEF head") confers a pronounced bulky hydrophobic nature to the Aβ N terminus that might explain the enhanced aggregation properties of the modified peptide. The deep burial of the pEF head by two of the antibodies explains their high target specificity and low cross-reactivity, making them promising candidates for the development of clinical antibodies.

PubMed: 28623233
DOI: 10.1074/jbc.M117.777839

Experimental method

X-RAY DIFFRACTION (2.211 Å)